Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)-Reference-Cited by-同舟云学术

Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)

Published:2022-12-08 Issue:5 Volume:128 Page:877-885
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Orsi Giulia,Cavaliere Alessandro,Tortora Giampaolo^ORCID,Lonardi Sara^ORCID,Macchini Marina,Di Marco Mariacristina,Giordano Guido,Vasile Enrico,Scartozzi Mario^ORCID,Bozzarelli Silvia,Noventa Silvia,Rodriquenz Maria Grazia,Militello Anna Maria,Rapposelli Ilario Giovanni,Garajova Ingrid^ORCID,De Lorenzo Stefania,Merelli Barbara,Bittoni Alessandro,Salvatore Lisa,Procaccio Letizia,Paratore Chiara,Spallanzani Andrea,Peretti Umberto,Niger Monica^ORCID,Giommoni Elisa,Bernardini Ilaria,Tamburini Emiliano,Bernardino Katia,Forti Laura,Valente Maria Maddalena,Cascinu Stefano,Milella Michele,Reni Michele^ORCID

Funder

MyEverest ONLUS

MyEVerest ONLUS

This study was partially supported by MyEverest ONLUS (no grant number).

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-022-02086-w.pdf

Reference27 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.